McKesson (MCK)
(Delayed Data from NYSE)
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$525.28 USD
-0.66 (-0.13%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $525.55 +0.27 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Should Value Investors Choose McKesson Corp (MCK) Stock?
by Zacks Equity Research
Let's see if McKesson Corp (MCK) stock is a good choice for value-oriented investors right now from multiple angles.
Why Is McKesson (MCK) Up 8.9% Since Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Company News for Nov 4, 2020
by Zacks Equity Research
Companies In The News Are: W, HUM, MCK, CRUS
McKesson (MCK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter 2021 results benefit from strong segmental performance.
McKesson (MCK) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 24.03% and 2.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) to Post Q2 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
MCK or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MCK vs. WST: Which Stock Is the Better Value Option?
Dental Market Picks Up Pace Amid COVID-19: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on potentially strong three stocks in the dental space that have shown promise during the pandemic.
Nevro Bolsters Growth Prospects With New Manufacturing Plan
by Zacks Equity Research
Nevro (NVRO) commences plan for manufacturing operations in Costa Rica, thereby expanding its geographic footprint and boosting growth prospects.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
McKesson (MCK) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson Extends Partnership With CDC to Fight Coronavirus
by Zacks Equity Research
McKesson (MCK) extends partnership with the CDC to aid in the distribution of future COVID-19 vaccines.
Company News for Aug 4, 2020
by Zacks Equity Research
Companies In The News Are: TSN, MCK, MCY, TKR.
McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2021 results benefit from strong U.S. Pharmaceutical and Specialty Solutions segment.
McKesson (MCK) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 17.87% and 3.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
Earnings Preview: McKesson (MCK) Q1 Earnings Expected to Decline
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Near-Term Outlook Bleak for Medical Dental Supplies Industry
by Trina Mukherjee
Digital influence coupled with AI & Robotics can drive the medical dental supplies industry amid the coronavirus-induced crisis.
McKesson (MCK) Up 5.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
McKesson (MCK) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2020 results benefit from strong segmental performance.
McKesson (MCK) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 4.15% and 5.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?